Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SteadyTeq
- Development stage
- Unknown
- Lead developer
- Teva Pharmaceutical
- Modality
- Hydrogel Systems → Drug Delivery Systems, Small Molecules
- Administration
- Subcutaneous
01
Overview
SteadyTeq is a proprietary copolymer-based drug delivery technology developed by MedinCell and licensed to Teva Pharmaceuticals. It serves as the delivery platform for UZEDY (risperidone), an FDA-approved extended-release injectable suspension for the treatment of schizophrenia and the maintenance treatment of bipolar I disorder in adults. The technology, internally referred to by MedinCell as BEPO, creates a subcutaneous biodegradable depot that slowly releases risperidone—an atypical antipsychotic—over a period of one or two months. This formulation allows for rapid therapeutic onset (within 6–24 hours) and eliminates the requirement for oral supplementation or loading doses typically associated with long-acting injectables.
- Brand names
- UZEDY
- Other names
- BEPO
02
Targets
DRD2 (Dopamine D2 Receptor)HTR2A (Serotonin receptor 5-HT2A)
Beyond the preview
Go deeper on SteadyTeq.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SteadyTeq.